Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades.

× No keyword cloud information.

14 in total

1. Second Workshop of the European Paediatric Network for Haemophilia Management, 17-19 September 1998 in Vitznau/Switzerland.

Authors: R Ljung
Journal: Haemophilia Date: 1999-07 Impact factor: 4.287

2. Guidelines for the management of hemophilia.

Authors: A Srivastava; A K Brewer; E P Mauser-Bunschoten; N S Key; S Kitchen; A Llinas; C A Ludlam; J N Mahlangu; K Mulder; M C Poon; A Street
Journal: Haemophilia Date: 2012-07-06 Impact factor: 4.287

3. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?

Authors: P Petrini
Journal: Haemophilia Date: 2001-01 Impact factor: 4.287

4. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized.

Authors: J Astermark; P Petrini; L Tengborn; S Schulman; R Ljung; E Berntorp
Journal: Br J Haematol Date: 1999-06 Impact factor: 6.998

Review 5. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.

Authors: Michael Richards; Michael Williams; Elizabeth Chalmers; Ri Liesner; Peter Collins; Vicky Vidler; John Hanley
Journal: Br J Haematol Date: 2010-03-11 Impact factor: 6.998

6. [French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemophiliac arthropathy].

Authors: S Meunier; M Trossaërt; C Berger; A Borel-Derlon; G Dirat; S Donadel-Claeyssens; A Durin Assolant; C Guérois; P Lutz; A Rafowicz; C Rothschild; H Chambost
Journal: Arch Pediatr Date: 2009-12 Impact factor: 1.180

7. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study.

Authors: Samantha C Gouw; Johanna G van der Bom; H Marijke van den Berg
Journal: Blood Date: 2007-02-08 Impact factor: 22.113

8. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.

Authors: K Kurnik; C Bidlingmaier; W Engl; H Chehadeh; B Reipert; G Auerswald
Journal: Haemophilia Date: 2009-10-29 Impact factor: 4.287

9. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.

Authors: Samantha C Gouw; H Marijke van den Berg; Kathelijn Fischer; Günter Auerswald; Manuel Carcao; Elizabeth Chalmers; Hervé Chambost; Karin Kurnik; Ri Liesner; Pia Petrini; Helen Platokouki; Carmen Altisent; Johannes Oldenburg; Beatrice Nolan; Rosario Pérez Garrido; M Elisa Mancuso; Anne Rafowicz; Mike Williams; Niels Clausen; Rutger A Middelburg; Rolf Ljung; Johanna G van der Bom
Journal: Blood Date: 2013-04-03 Impact factor: 22.113

Review 10. The risk associated with indwelling catheters in children with haemophilia.

Authors: Rolf Ljung
Journal: Br J Haematol Date: 2007-09 Impact factor: 6.998

1 in total

1. The importance of genetic factors for the development of arthropathy: a longitudinal study of children and adolescents with haemophilia A.

Authors: Edward D Gomperts; John Schwarz; Sharyne M Donfield; Alice E Lail; Jan Astermark; W Keith Hoots; Cheryl A Winkler; Erik Berntorp
Journal: Thromb Haemost Date: 2016-12-08 Impact factor: 5.249

1 in total